Publikationen, an denen er mitarbeitet Ramón Lecumberri Villamediana (18)

2021

  1. Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis

    Leukemia, Vol. 35, Núm. 1, pp. 245-249

  2. Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development

    Blood, Vol. 138, Núm. 17, pp. 1583-1589

2019

  1. Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    TH Open

  2. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

  3. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

2018

  1. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

2017

  1. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2016

  1. Cancer screening after unprovoked venous thrombosis

    The Lancet Oncology

  2. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

  3. La aplicación de un protocolo de gestión para la hemorragia masiva reduce la mortalidad en pacientes con hemorragia no traumática: Resultados de la auditoría de un centro

    Medicina Intensiva, Vol. 40, Núm. 9, pp. 550-559

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

  2. Short-term heparin re-exposure during heart transplantation in patients with ventricular assist devices and acute heparin-induced thrombocytopenia

    Revista Espanola de Cardiologia

2014

  1. Seguridad y eficacia de un concentrado de complejo protrombínico en pacientes con coagulopatía y hemorragia

    Anales del sistema sanitario de Navarra, Vol. 37, Núm. 3, pp. 363-369

2013

  1. Dynamics of case-fatalilty rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism

    Thrombosis and Haemostasis, Vol. 110, Núm. 4, pp. 834-843

  2. High incidence of venous thromboembolism despite electronic alerts for thromboprophylaxis in hospitalised cancer patients

    Thrombosis and Haemostasis, Vol. 110, Núm. 1, pp. 184-190

  3. Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission

    Clinical Cancer Research, Vol. 19, Núm. 17, pp. 4770-4779

  4. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism

    International Journal of Cancer, Vol. 133, Núm. 9, pp. 2157-2164

2003

  1. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181